Liang Cheng, President of International Society of Urological Pathology, Vice Chair for Translational Research at The Warren Alpert Medical School of Brown University, shared a post on X:
“March 2026 Special Issue on Biomarker Testing in Urologic Malignancies is now available in Current Opinion in Urology.
Check it out here:
It was my great honor to co-edit this special issue with the distinguished Professor Eva Comperat.
Urologic pathology has undergone rapid and transformative change in recent years. Molecular biomarker testing is reshaping how urologic tumors are classified, treated, and monitored over time. Traditional morphologic diagnosis – long the cornerstone of surgical pathology – has evolved into a multidimensional discipline that integrates histopathology, immunohistochemistry, molecular diagnostics, digital pathology, and emerging computational tools.
This evolution parallels major advances in precision oncology, where cancer genomics, targeted therapy, immunotherapy, and risk-stratified management increasingly depend on accurate pathologic diagnosis and robust molecular biomarker testing.
The present special issue of Current Opinion in Urology brings together ten invited state-of-the-art reviews highlighting recent advances, persistent challenges, and future directions in the modern practice of urologic surgical pathology.
A central theme across the issue is the reaffirmation of pathology as a cornerstone of urologic cancer management. Precise interpretation of urologic surgical specimens directly influences eligibility for active surveillance, assessment of surgical adequacy, selection of systemic therapies, and prediction of treatment response.
Collectively, the articles in this issue underscore the critical role of urologic pathologists in patient management, therapeutic selection, and outcome prediction. The integration of morphology with molecular data is fundamental to advancing precision medicine. Together, these contributions portray a discipline in transition – one that is increasingly data-driven, technologically sophisticated, and deeply integrated into clinical decision-making.
As urologic oncology continues to evolve, pathologists remain pivotal in translating scientific innovation into real-world clinical applications.”
Other articles featuring Liang Cheng on OncoDaily.
